Drug-induced renal failure: Update on new medications and unique mechanisms of nephrotoxicity

American Journal of the Medical Sciences

Volumn 325, Issue 6, 2003, Pages 349-362

  Perazella, Mark A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Crystal nephropathy; Drugs; Medications; Nephrotoxicity; Osmotic nephrosis; Renal failure

Indexed keywords

ACICLOVIR; ADEFOVIR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIPARASITIC AGENT; ANTIVIRUS AGENT; CIDOFOVIR; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HETASTARCH; IMMUNOGLOBULIN; INDINAVIR; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PLASMA SUBSTITUTE; PROTEINASE INHIBITOR; SULFADIAZINE; SULFONAMIDE; TENOFOVIR;

ANALGESIC NEPHROPATHY; CONGESTIVE HEART FAILURE; EDEMA; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPONATREMIA; INTERSTITIAL NEPHRITIS; KIDNEY BLOOD FLOW; KIDNEY CANCER; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY PAPILLA NECROSIS; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE DISORDER; MEMBRANOUS GLOMERULONEPHRITIS; METABOLIC ACIDOSIS; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHROSIS; NEPHROTIC SYNDROME; NEPHROTOXICITY; REVIEW;

EID: 0038178864     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200306000-00006     Document Type: Review

References (135)

1. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:413-21.
2. Crofford LJ. COX-1 and COX-2 Tissue expression: Implications and predictions. J. Rheumatol 1997;24(Suppl 49):15-9.
3. Siverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drug for osteoarthritis and rheumatoid arthritis. JAMA 2000;284:1247-55.
4. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
5. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984;310:563-72.
6. Schlondorf D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 1993;44:643-53.
7. Smith WL, DeWitt DL. Biochemistry and prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol 1995;15:179-94.
8. Komhoff M, Grone H-J, Klein T, et al. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am. J. Physiol. 1997;272:F460-F468.
9. Hao CM, Komhoff M, Guan Y, et al. Selective targeting of cyclooxygenase-2 reveals its role in renal medullary interstitial survival. Am J Physiol 1999;277:F352-F359.
10. Harris RC, McKanna JA, Akai Y, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994;94:2504-10.
11. Fitzpatrick FA, Soberman R. Regulated formation of eicosanoids. J Clin Invest 2001;107:1347-51.
12. Smith WL, Lagenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 2001;107:1491-5.
13. Palmer BF, Henrich WL. Clinical acute renal failure with nonsteroidal anti-inflammatory drugs. Semin Nephrol 1995;15:214-27.
14. Niwa T, Maeda K, Shibata M. Urinary prostaglandins and thromboxane in patients with chronic glomerulonephritis. Nephron 1987;46:281-7.
15. Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1982;263:F181-F187.
16. Breyer MD, Harris RC. Cyclooxygenase 2 and the kidney. Curr Opin Nephrol Hypertension 2001;10:89-98.
17. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991;31:588-98.
18. Guan Y, Chang M, Cho W, et al. Cloning, expression, and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells. Am J Physiol 1997;273:F18-F26.
19. Ohnaka K, Numaguchi K, Yamaka W, et al. Induction of cyclooxygenase-2 by angiotensin II in cultured rat vascular smooth muscle cells. Hypertension 1999;35:68-75.
20. Yang T, Singh I, Pham H, et al. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol 1998;274:F481-F489.
21. Kester M, Coroneous E, Thomas P, et al. Endothelin stimulates prostaglandin endoperoxide synthase-2 mRNA expression and protein synthesis through tyrosine kinase signaling pathway in rat cells. J Biol Chem 1994;269:22574-22580.
22. Ferreri NR, An SJ, McGiff JC. Cyclooxygenase-2 expression and function in the medullary thick ascending limb. Am J Physiol 1999;277:F360-F368.
23. Harris RC, Breyer MD. Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol 2001;281:F1-F11.
24. Traynor TR, Smart A, Briggs JP, et al. Inhibition of macula densa-stimulated renin secretion by pharmacological blockade of cyclooxygenase-2. Am J Physiol 1999;277:F706-F710.
25. Yang T, Schnermann JB, Briggs JP. Regulation of cyclooxygenase-2 expression in renal medulla by tonicity in vivo and in vitro. Am J Physiol 1999;277:F1-F9.
26. Hao CM, Yull F, Blackwell T, et al. Dehydration activates an NF-κB-driven, COX2-dependent survival mechanism in renal medullary interstitial cells. J Clin Invest 2000;106:973-82.
27. Abassi Z, Brodsky S, Gealekman O, et al. Intrarenal expression and distribution of cyclooxygenase isoforms in rats with experimental heart failure. Am J Physiol Renal Physiol 2001;280:F43-F53.
28. Llinas MT, Lopez R, Rodriguez F, et al. Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine. Am J Physiol Renal Physiol 2001;281:F975-F982.
29. Kammerl MC, Nusing RM, Richthammer W, et al. Inhibition of COX-2 counteracts the effects of diuretics in rats. Kidney Int 2001;60:1684-91.
30. Muscara MN, Vergnolle N, Lovren F, et al. Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol 2000;129:1423-30.
31. Nantel F, Meadows E, Denis D, et al. Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS Lett 1999;457:475-7.
32. Komhoff M, Jeck NDM, Seyberth HW, et al. Cyclooxygenase-2 expression is associated with the renal macula densa of patients with Bartter-like syndrome. Kidney Int 2000;58:2410-24.
33. Rossat J, Maillard M, Nussberger J, et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999;66:76-84.
34. Swan SK, Lasster KC, Ryan CF, et. al. Effect of cyclooxygenase inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial Ann Intern Med 2000;133:1-9.
35. Perazella MA, Eras J. Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000;35:937-40.
36. Braden GL, O'Shea M, Mulhern J, et al. COX-2 inhibitor acute renal failure: Association with hyperkalemia & type IV renal tubular acidosis [abstract]. J Am Soc Nephrol 2000;11:126A.
37. Stafford C, Bestoso JT. Celecoxib-induced acute renal failure [abstract]. J Am Soc Nephrol 2000;11:134A.
38. Perazella MA, Tray K. Selective COX-2 inhibitors: A pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med 2001;111:64-67.
39. Graham MG. Acute renal failure related to high-dose celecoxib. Ann Intern Med 2001;135:69-70.
40. Pfister AK, Crisalli RJ, Carter WH. Cyclooxygenase-2 inhibition and renal function [letter]. Ann Intern Med 2001;134:1077.
41. Rocha JL, Fernandez-Alonso J. Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. Lancet 2001;357:1946-7.
42. Gadalean F, Barreto G, Epstein M. Acute renal failure induced by COX-2 specific inhibitors [abstract]. J Am Soc Nephrol 2001;12:779A.
43. Navar LG, Harrison-Bernard LM, Imig JD, et al. Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. J Am Soc Nephrol 1999;10:S266-S272.
44. Packer M, Lee WH, Medina N, et al. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe congestive heart failure. Ann Intern Med 1987;106:346-55.
45. Lalezari JP. Cidofovir: a new therapy for cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:S22-S26.
46. Lalezari JP, Kuppermann BD. Clinical experience with cidofovir in the treatment of cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:S27-S31.
47. Anonymous. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Ann Intern Med 1997;126:264-74.
48. Lalezari JP, Holland GN, Kramer F, et al. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:339-44.
49. Meier P, Dautheville-Guibal S, Ronco PM, et al. Cidofovir-induced end-stage renal failure. Nephrol Dial Transplant 2002;17:148-9.
50. Cundy KC, Barditch-Crovo P, Walker RE, et al. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 1995;39:2401-5.
51. Fisher E, Brosgart C, Cohn D, et al. Safety of adefovir dipivoxil (ADV) and incidence of proximal tubular disorders (PRTD) in a placebo-controlled trial in patients with advanced HIV disease. Proceedings of the 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago, Illinois. Alexandria (VA): Foundation for Retrovirology and Human Health; 1999. [Abstract 678]
52. Ho ES, Lin DC, Mendel DB, et al. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 2000;11:383-93.
53. Cihlar T, Lin DC, Pritchard JB, et al. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 1999;56:570-80.
54. Roch-Ramel F. Renal transport of organic anions. Curr Opin Nephrol Hypertens 1998;7:517-24.
55. Sweet D, Wolff N, Pritchard J. Expression cloning and characterization of ROAT1. J Biol Chem 1997;272:30088-30095.
56. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002;16:1257-63.
57. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001;45:2733-9.
58. Coca S, Perazella MA. Acute Renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity Am J Med Sci 2002;324:342-4.
59. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002;40:1331-3.
60. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-93.
61. Hortbagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998;16:2038-44.
62. Physician's desk reference. 54th ed. Montvale (NJ): Medical Economics Company; 2000. Pamidronate; p. 1998-2002.
63. Green JR, Seltenmeyer Y, Jaeggi KA, et al. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol 1997;80:225-30.
64. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001;12:1164-72.
65. Lockridge L, Papac RJ, Perazella MA. Pamidronate-associated nephrotoxicity in a patient with Langerhan's histiocytosis. Am J Kidney Dis 2002;40:E2.
66. Rey J, Daumen-Legre V, Pham T, et al. Uveitis, an under-recognized adverse effect of pamidronate. Joint, Bone, Spine 2000;67:337-40.
67. Machado CE, Flombaum CD. Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol 1996;45:175-9.
68. Ali SM, Esteva FJ, Hortobagyi G, et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001;19:3434-7.
69. Shankland SJ, Eitner F, Hudkins KL, et al. Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease. Role in podocyte proliferation and maturation. Kidney Int 2000;58:674-83.
70. Berns JS, Cohen RM, Stumacher RJ, et al. Renal aspects of therapy for human immunodeficiency virus and associated oppurtunistic infections. J Am Soc Nephrol 1991;1:1061-80.
71. Fogazzi GB. Crystalluria: a neglected aspect of urinary sediment analysis. Nephrol Dial Transplant 1996;11:379-87.
72. Conger JD. Acute uric acid nephropathy. Med Clin North Am 1990;74:384-92.
73. Ogea Garcia JL, Villanueva Marcos JL, Jurado R. Burkitt's lymphoma and AIDS. Their presentation as tumoral hepatomegaly and acute kidney failure due to tubular deposit of urates. Ann Intern Med 1993;118:37-39.
74. Perazella MA, Brown E. Electrolyte and acid-base disorders associated with AIDS: An etiologic review. J Gen Intern Med 1994;9:232-6.
75. Simon DI, Brosius FC, Rothstein DM. Sulfadiazine-induced crystalluria revisted. The treatment of Toxoplasma encephalitis in patients with acquired immune defiency syndrome Arch Intern Med 1990;150:2379-84.
76. Carbone LG, Bendixen B, Appel GB. Sulfadiazine-associated obstructive nephropathy occurring in a patient with acquired immune deficiency syndrome. Am J Kidney Dis 1988;12:72-75.
77. Hein R, Brunkhorst R, Thon WF. Symptomatic sulfadiazine crystalluria in AIDS patients: A report of two cases. Clin Nephrol 1993;39:254-6.
78. Sasson JP, Dratch PL, Shortsleeve MJ. Renal ultrasound findings in sulfadiazine-induced crystalluria. Radiology 1992;185:739-40.
79. Molina JM, Belenfant X, Doco-Lecompte T. Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis. AIDS 1991;5:587-9.
80. de Sequera P, Albalate M, Hernandez J, et al. Acute renal failure due to sulfadiazine crystalluria in AIDS patients. Postgrad Med J 1996;72:557-8.
81. Diaz F, Collazos J, Mayo J, et al. Sulfadiazine-induced multiple urolithiasis and acute renal failure in a patient with AIDS and Toxoplasma encephalitis. Ann Pharmacol 1996;30:41-42.
82. Sawyer MH, Webb DE, Balow JE, et al. Acyclovir-induced renal failure. Clinical course and histology. Am J Med 1988;84:1067-71.
83. Brigden D, Rosling AE, Woods NC. Renal function after acyclovir intravenous injection. Am J Med 1982;73(Suppl 1A):182-5.
84. Keeney RF, Kirk LE, Brigden D. Acyclovir tolerance in humans. Am J Med 1982;73(Suppl 1A):176-81.
85. Bean B, Aeppli D. Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster. J Infect Dis 1985;151:362-5.
86. Giustina A, Romanelli G, Cimino A, et al. Low dose acyclovir and acute renal failure [letter]. Ann Intern Med 1988;108:312.
87. Eck P, Silver SM, Clark EC. Acute renal failure and coma after a high dose of oral acyclovir [letter]. N Engl J Med 1991;325:1178.
88. Dos Santos M, Dos Santos OF, Boim MA, et al. Nephrotoxicity of acyclovir and ganciclovir in rats: Evaluation of glomerular hemodynamics. J Am Soc Nephrol 1997;8:361-7.
89. Krieble BF, Rudy DW, Glick MR, et al. Acyclovir neurotoxicity and nephrotoxicity-the role for hemodialysis. Am J Med Sci 1993;305:36-39.
90. Gulick R, Mellors J, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with Human Immunodeficiency Virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
91. Tashima KT, Horowitz JD, Rosen S. Indinavir nephropathy (letter). N Engl J 8 Med 1997;336:138-9.
92. Perazella MA, Kashgarian M, Cooney E. Indinavir nephropathy in an HIV-infected patient with renal insufficiency and pyuria. Clin Nephrol 1998;50:194-6.
93. Daudon M, Estepa L, Viard JP, et al. Urinary stones in HIV-1 positive patients treated with indinavir. Lancet 1997;349:1294-305.
94. Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997;127:119-25.
95. Bach MC, Godofsky EW. Indinavir nephrolithiasis in warm climates [letter]. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:296-7.
96. Berns JS, Cohen RM, Silverman M, et al. Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases. Am J Kidney Dis 1997;30:558-60.
97. Grunke M, Valerius T, Manger B, et al. Renal dysfunction in a Human Immunodeficiency Virus-infected patient who was treated with indinavir. Clin Infect Dis 1997;25:1270-1.
98. Reilly RF, Tray K, Perazella MA. Indinavir nephropathy revisited: pattern of insidious renal failure with identifiable risk factors. Am J Kidney Dis 2001;38:E23-E28.
99. Anderson W, Bethea W. Renal lesions following administration of hypertonic solutions of sucrose. JAMA 1940;114:1983-7.
100. Lindberg H, Wald M. Renal changes following the administration of hypertonic solutions. Arch Int Med 1939;63:907-18.
101. Rigdon RH, Cardwell ES. Renal lesions following the intravenous injection of hypertonic solution of sucrose: a clinical and experimental study. Arch Int Med 1942;69:670-90.
102. DiScala V, Mautner W, Cohen J, et al. Tubular alterations produced by osmotic diuresis with mannitol. Ann Int Med 1965;63:767-75.
103. Morgan T, Little J, Evans W. Acute renal failure associated with low-molecular weight dextran infusion. Brit Med J 1966;2:737-9.
104. Anonymous. ASHP therapeutic guidelines for intravenous immune globulin. ASHP Commission on Therapeutics. Clin Pharm 1992;11:117-36.
105. Barton J, Herrera G, Galla J, et al. Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin. Am J Med 1987;82:624-9.
106. Schifferli J, Leske M, Favre H, et al. High dose intravenous IgG treatment and renal function. Lancet 991;337:457-8.
107. Rault R, Piraino B, Johnston J, et al. Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol 1991;36:83-86.
108. Ellie E, Combe C, Ferrer X. High-dose intravenous immune globulin and acute renal failure. N Engl J Med 1992;327:1032-3.
109. Stewart R, Winney R, Cash J. Renal toxicity of intravenous immunoglobulin [letter]. Vox Sang 1993;65:244.
110. Ruggeri M, Castaman G, de Narde G, et al. Acute renal failure after high-dose intravenous immune globulin in a patient with Idiopathic Thrombocytopenic Purpura. Haematologica 1993;78:338-9.
111. Pasatiempo A, Kroser J, Ruducek M, et al. Acute renal failure after intravenous immunoglobulin therapy. J Rheumatol 1994;21:347-9.
112. Ahsan N, Palmer B, Wheeler D, et al. Intravenous immunoglobulin-induced osmotic nephrosis. Arch Intern Med 1994;154:1985-7.
113. Cantu T, Hoehn-Saric E, Burgess K, et al. Acute renal failure associated with immunoglobulin therapy. Am J Kid Dis 1995;25:228-34.
114. Poullin P, Moulen B, Ollier J, et al. Hyperoncotic renal failure after intravenous immunoglobulin therapy. Presse Med 1995;24:441-4.
115. Arunabh S, Kuman G, Avila V. Acute renal failure induced by intravenous immune globulin. Am Fam Physician 1996;53:862-3.
116. Corvetta A, Della Bitta R, Gabriella A, et al. Use of high dose intravenous immunoglobulin in systemic lupus erythematosus: report of three cases. Clin Exp Rheum 1989;7:295-9.
117. Rostoker G, Philippon C, Belghitti D, et al. Intravenous IgG for glomerulonephritis and renal function. Lancet 1991;338:544-55.
118. Kobosko J, Nicol P. Renal toxicity of intravenous immunoglobulin. Clin Nephrol 1992;37:216-7.
119. Phillips AO. Renal failure and intravenous immunoglobulin [letter]. Clin Nephrol 1992;37:217.
120. Donatini B. Transient renal dysfunction in diabetic patients after IVIG therapy [letter]. J Int Med 1992;232:376.
121. Tan E, Hajinazarian M, Bay W, et al. Acute renal failure resulting from intravenous immmunoglobulin therapy. Arch Neurol 1993;50:137-9.
122. Winward DB, Brophy MT. Acute renal failure after administration of intravenous immunoglobulin: review of the literature and case report. Pharmacotherapy 1995;15:765-72.
123. Hansen-Schmidt S, Silomon J, Keller F. Osmotic nephrosis due to high dose immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis. Am J Kidney Dis 1996;28:451-3.
124. Friedman KD, Saddler MC, Tarnover AC, et al. Transient renal failure in a patient with idiopathic thrombocytopenic purpura after treatment with concomitant protein-A immunosorption and intravenous immune globulin. Blood 1992;80(Suppl 1):483a.
125. Tsinalis D, Dickenmann M, Brunner F, et al. Acute renal failure in a renal allograft recipient treated with intravenous immunoglobulin. Am J Kidney Dis 2002;40:667-70.
126. Schwartz SL, Johnson CB. Pinocytosis as cause of sucrose nephrosis. Nephron 1971;8:246-54.
127. Cayco AV, Perazella MA, Hayslett JP. Renal insufficiency following intravenous immune globulin therapy: a report of two cases and analysis of the literature. J Am Soc Nephrol 1997;8:1788-94.
128. Legendre C, Thervet E, Page B, et al. Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 1993;342:248-9.
129. Cittanova ML, Lebanc I, Legendre C, et al. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996;348:1620-2.
130. Deman A, Peeters P, Sennesael J. Hydroxyethyl starch does not impair immediate renal function in kidney transplant recipients: a retrospective, multicentre analysis. Nephrol Dial Transplant 1999;14:1517-20.
131. Bernard C, Alain M, Simone C, et al. Hydroxyethylstarch and osmotic nephrosis-like lesions in kidney transplants. Lancet 1996;348:1595.
132. LaBarthe AD, Jacobs F, Blot F. Acute renal failure secondary to hydroxyethylstarch administration in a surgical patient. Am J Med 2001;111:417-8.
133. Dickenmann MJ, Filipovic M, Schneider MC, et al. Hydroxyethylstarch-associated transient acute renal failure after epidural anaesthesia for labour analgesia and caesarean section. Nephrol Dial Transplant 1998;13:2706.
134. Schortgen F, Lacherade JC, Brunner F, et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001;357:911-6.
135. Edwards CA, Knoll GA. Hydroxyethylstarch (HES) and the risk of delayed graft function (DGF) following renal transplantation. J Am Soc Nephrol 2002;13:375-376A.